Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study

[1]  W. van Hecke,et al.  Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study. , 2020, Multiple sclerosis and related disorders.

[2]  L. Kappos,et al.  Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP) , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[3]  K. Anja.  European Committee for Treatment and Research in Multiple Sclerosis , 2019, Kinder- und Jugendmedizin.

[4]  P. Vermersch,et al.  The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. , 2019, Multiple sclerosis and related disorders.

[5]  S. Galetta,et al.  Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE , 2019, BMC Neurology.

[6]  R. Bakshi,et al.  Magnetic Resonance Imaging in Multiple Sclerosis. , 2018, Cold Spring Harbor perspectives in medicine.

[7]  S. Richman,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies , 2017, The Lancet Neurology.

[8]  C. Pozzilli,et al.  Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis , 2016, Journal of the Neurological Sciences.

[9]  D. Reich,et al.  Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis , 2016, American Journal of Neuroradiology.

[10]  D. Campagnolo,et al.  Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy , 2014, Annals of neurology.

[11]  L. Kappos,et al.  Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  Meena Subramanyam,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.

[13]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[14]  K. Simon,et al.  Anti‐JC virus antibodies: Implications for PML Risk Stratification , 2010, Annals of neurology.

[15]  C. Polman,et al.  Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study , 2009, The Lancet Neurology.

[16]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[17]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.